A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://ncbi.nlm.nih.gov/pubmed/24373380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-613
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires